Publications by authors named "H E Haysom"

Background: The provision of ABO-incompatible fresh frozen plasma (FFP) in massive transfusion (MT) has become accepted to conserve AB FFP stock. There is an evidence gap in non-trauma settings. We compare characteristics of patients who received ABO-compatible or ABO-incompatible FFP during an MT episode due to any cause of critical bleeding, and assess the impact of incompatible FFP transfusion on inhospital mortality.

View Article and Find Full Text PDF
Article Synopsis
  • This study examines ultra-massive transfusion (UMT) events in patients receiving 20 or more units of red blood cells (RBCs) within 48 hours, using data from the Australian and New Zealand Massive Transfusion Registry (ANZ-MTR).
  • Of the 9028 patients analyzed, 803 (8.9%) experienced UMT, with younger patients and those in trauma or cardiothoracic surgery contexts being more prevalent.
  • UMT cases showed higher in-hospital mortality compared to massive transfusion cases (20.5% vs. 44.2%), yet 55.8% of UMT patients survived to discharge, indicating that despite higher risks, UMT isn't futile as long
View Article and Find Full Text PDF

Background: Sickle cell disease (SCD) is the most common monogenic disorder worldwide. In deoxygenated conditions, the altered beta chain (haemoglobin S [HbS]) polymerises and distorts the erythrocyte, resulting in pain crises, vasculopathy and end-organ damage. Clinical complications of SCD cause substantial morbidity, and therapy demands expertise and resources.

View Article and Find Full Text PDF

Background: In the context of critical bleeding and massive transfusion (CB/MT), little is known about the development of new red blood cell (RBC) alloantibodies. We performed a retrospective, observational study to examine the frequency of RBC alloantibodies (pre-existent, anamnestic, or new) in patients with CB/MT, defined as transfusion of five or more RBC units in any 4-hour period, for any cause of CB.

Materials And Methods: Data on 2,585 New Zealand patients (date/time of MT initiation, demographic data, blood group, clinical context, and transfused RBCs) were obtained from the Australian and New Zealand Massive Transfusion Registry.

View Article and Find Full Text PDF

Background: Children affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) are at risk of severe intracranial haemorrhage. Management in the postnatal period is based on sparse evidence. We aimed to describe the contemporary management and outcomes of patients with FNAIT in high-income countries.

View Article and Find Full Text PDF